Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HJB647 low dose · 1 trial · 1 indication
Number of participants with AEs as a measure of safety and tolerability
Number of participants with clinically significant changes in Systolic Blood Pressure, Diastolic Blood Pressure, Heart Rate, Electrocardiogram and hyposensitive events as a measure of adverse events
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Taken by mouth as capsules |
| HJB647 low dose | EXPERIMENTAL | Taken by mouth as capsule |
| HJB647 high dose | EXPERIMENTAL | Taken by mouth as capsule |
| Name | Type | Description |
|---|---|---|
| HJB647 low dose | DRUG | Study drug low dose in capsule form |
| HJB647 high dose | DRUG | Study drug high dose in capsule form |
| Placebo | OTHER | Placebo control in capsule form |
Inclusion Criteria: Participants eligible for inclusion in this study must meet all of the following criteria: * Men and women aged 18 years or older * Stable NYHA functional class II-III * LVEF \<50% * NT-proBNP ≥600 pg/ml if in sinus rhythm or ≥900 pg/ml if in atrial fibrillation at screening * ...